BACKGROUND: In the normal heart, phosphodiesterase type 5 (PDE5) hydrolyzes cGMP coupled to nitric oxide- (specifically from nitric oxide synthase 3) but not natriuretic peptide (NP)-stimulated guanylyl cyclase. PDE5 is upregulated in hypertrophied and failing hearts and is thought to contribute to their pathophysiology. Because nitric oxide signaling declines whereas NP-derived cGMP rises in such diseases, we hypothesized that PDE5 substrate selectivity is retargeted to blunt NP-derived signaling. METHODS AND RESULTS: Mice with cardiac myocyte inducible PDE5 overexpression (P5(+)) were crossed to those lacking nitric oxide synthase 3 (N3(-)), and each model, the double cross, and controls were subjected to transaortic constriction. P5(+) mice developed worse dysfunction and hypertrophy and enhanced NP stimulation, whereas N3(-) mice were protected. However, P5(+)/N3(-) mice behaved similarly to P5(+) mice despite the lack of nitric oxide synthase 3-coupled cGMP generation, with protein kinase G activity suppressed in both models. PDE5 inhibition did not alter atrial natriuretic peptide-stimulated cGMP in the resting heart but augmented it in the transaortic constriction heart. This functional retargeting was associated with PDE5 translocation from sarcomeres to a dispersed distribution. P5(+) hearts exhibited higher oxidative stress, whereas P5(+)/N3(-) hearts had low levels (likely owing to the absence of nitric oxide synthase 3 uncoupling). This highlights the importance of myocyte protein kinase G activity as a protection for pathological remodeling. CONCLUSIONS: These data provide the first evidence for functional retargeting of PDE5 from one compartment to another, revealing a role for natriuretic peptide-derived cGMP hydrolysis by this esterase in diseased heart myocardium. Retargeting likely affects the pathophysiological consequence and the therapeutic impact of PDE5 modulation in heart disease.
BACKGROUND: In the normal heart, phosphodiesterase type 5 (PDE5) hydrolyzes cGMP coupled to nitric oxide- (specifically from nitric oxide synthase 3) but not natriuretic peptide (NP)-stimulated guanylyl cyclase. PDE5 is upregulated in hypertrophied and failing hearts and is thought to contribute to their pathophysiology. Because nitric oxide signaling declines whereas NP-derived cGMP rises in such diseases, we hypothesized that PDE5 substrate selectivity is retargeted to blunt NP-derived signaling. METHODS AND RESULTS: Mice with cardiac myocyte inducible PDE5 overexpression (P5(+)) were crossed to those lacking nitric oxide synthase 3 (N3(-)), and each model, the double cross, and controls were subjected to transaortic constriction. P5(+) mice developed worse dysfunction and hypertrophy and enhanced NP stimulation, whereas N3(-) mice were protected. However, P5(+)/N3(-) mice behaved similarly to P5(+) mice despite the lack of nitric oxide synthase 3-coupled cGMP generation, with protein kinase G activity suppressed in both models. PDE5 inhibition did not alter atrial natriuretic peptide-stimulated cGMP in the resting heart but augmented it in the transaortic constriction heart. This functional retargeting was associated with PDE5 translocation from sarcomeres to a dispersed distribution. P5(+) hearts exhibited higher oxidative stress, whereas P5(+)/N3(-) hearts had low levels (likely owing to the absence of nitric oxide synthase 3 uncoupling). This highlights the importance of myocyte protein kinase G activity as a protection for pathological remodeling. CONCLUSIONS: These data provide the first evidence for functional retargeting of PDE5 from one compartment to another, revealing a role for natriuretic peptide-derived cGMP hydrolysis by this esterase in diseased heart myocardium. Retargeting likely affects the pathophysiological consequence and the therapeutic impact of PDE5 modulation in heart disease.
Authors: Xiaoyin Shan; Michael P Quaile; Jeffery K Monk; Benjamin French; Thomas P Cappola; Kenneth B Margulies Journal: Circ Heart Fail Date: 2011-12-01 Impact factor: 8.790
Authors: Zhongbing Lu; Xin Xu; Xinli Hu; Sangjin Lee; Jay H Traverse; Guangshuo Zhu; John Fassett; Yi Tao; Ping Zhang; Cris dos Remedios; Marc Pritzker; Jennifer L Hall; Daniel J Garry; Yingjie Chen Journal: Circulation Date: 2010-03-22 Impact factor: 29.690
Authors: Alessandra Stangherlin; Frank Gesellchen; Anna Zoccarato; Anna Terrin; Laura Ashley Fields; Marco Berrera; Nicoletta Concetta Surdo; Margaret Anne Craig; Godfrey Smith; Graham Hamilton; Manuela Zaccolo Journal: Circ Res Date: 2011-02-17 Impact factor: 17.367
Authors: Rita Holtwick; Martin van Eickels; Boris V Skryabin; Hideo A Baba; Alexander Bubikat; Frank Begrow; Michael D Schneider; David L Garbers; Michaela Kuhn Journal: J Clin Invest Date: 2003-05 Impact factor: 14.808
Authors: Ryuji Hataishi; Ana Clara Rodrigues; John G Morgan; Fumito Ichinose; Geneviève Derumeaux; Kenneth D Bloch; Michael H Picard; Marielle Scherrer-Crosbie Journal: Exp Physiol Date: 2006-03-09 Impact factor: 2.969
Authors: Eiki Takimoto; Diego Belardi; Carlo G Tocchetti; Susan Vahebi; Gianfrancesco Cormaci; Elizabeth A Ketner; An L Moens; Hunter C Champion; David A Kass Journal: Circulation Date: 2007-04-09 Impact factor: 29.690
Authors: Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello Journal: Nat Rev Drug Discov Date: 2014-04 Impact factor: 84.694
Authors: Sarah A Swager; Dawn A Delfín; Neha Rastogi; Honglan Wang; Benjamin D Canan; Vadim V Fedorov; Peter J Mohler; Ahmet Kilic; Robert S D Higgins; Mark T Ziolo; Paul M L Janssen; Jill A Rafael-Fortney Journal: Cardiovasc Pathol Date: 2014-11-07 Impact factor: 2.185
Authors: Dirk J Duncker; Elza D van Deel; Monique C de Waard; Martine de Boer; Daphne Merkus; Jolanda van der Velden Journal: Pflugers Arch Date: 2014-02-27 Impact factor: 3.657